EXPLANATORY NOTE
This Amendment No. 3 on Form40-F/A (this “Amendment”) for the year ended July 31, 2019 is being filed for the purpose of (i) filing restated audited annual consolidated financial statements of HEXO Corp. (the “Company”) for the fiscal year ended July 31, 2019 to correct identified errors in the Company’s financial statements for the fiscal year ended July 31, 2019 included in the Company’s previously filed Form40-F for the year ended July 31, 2019, as amended prior hereto (the “Prior Filing”), (ii) filing the related amended Management’s Discussion and Analysis for the fiscal year ended July 31, 2019, and (iii) filing an amended Annual Report for the year ended July 31, 2019 based on the restatement and amendment described in (i) and (ii). Dollar amounts are in expressed in thousands of Canadian dollars.
The deferred tax liability was overstated as at July 31, 2019, as it was not offset by a deferred tax asset relating to a tax loss generated in one subsidiary against a deferred tax liability generated by a separate subsidiary. Due to the two tax positions existing in two separate entities, the Company’s original position was that they could not be offset or reduce one another. The applicable subsidiaries were amalgamated on August 1, 2019. The correction of this error resulted in a reduction of the deferred tax liability and deficit, by $14,373, as at July 31, 2019. Additionally, net loss for the year ended July 31, 2019 was overstated by $14,373.
In assessing the financial impact of subsequent events, the Company has also adjusted the audited annual consolidated financial statements for the estimated fair market value of its cannabis trim based inventory due to new and available third-party information resulting in an increased impairment on inventory of $2,417. These corrections are noted in the‘Adjustments’ column in the restated audited annual consolidated financial statements accompanying this Amendment.
Additionally, pursuant to the rules of the U.S. Securities and Exchange Commission, this Amendment also contains (i) new certifications required by Rule13a-14(a) or Rule15d-14(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), (ii) new certifications required by Rule13a-14(b) or Rule15d-14(b) under the Exchange Act, and (iii) a new consent from the Company’s independent registered public accounting firm.
Other than as discussed above and expressly set forth herein, this Amendment does not, and does not purport to, amend or restate any other information contained in the Prior Filing nor does this Amendment reflect any events that have occurred after the filing date of the Prior Filing or November 13, 2019. The filing of this Amendment shall not be deemed an admission that the Prior Filing, when made, included any known, untrue statement of material fact or knowingly omitted to state a material fact necessary to make a statement not misleading.
RESTATED AUDITED ANNUAL FINANCIAL STATEMENTS
The restated audited consolidated financial statements of the Company for the year ended July 31, 2019, including the report of the independent auditors thereon, are filed as Exhibit 99.2 to this Amendment, and are incorporated by reference herein.
AMENDED MANAGEMENT’S DISCUSSION AND ANALYSIS
The Company’s amended Management’s Discussion and Analysis for the year ended July 31, 2019 is filed as Exhibit 99.3 to this Amendment, and is incorporated by reference herein.